Rtog 9410

[rymd]

---

Members do not see this ad.

It's arrived.

http://jnci.oxfordjournals.org/cont...full?sid=8fdeb975-3d2f-40bd-b8c8-baad3fddb243

ry

 

[Gfunk6]

Too bad they didn't publish 10 year f/u data . . .

 

[RadOncDoc21]

Any ideas why the study took so long to publish the data?

-R

 

[bix]

Dr. Zietman gave a great talk on this paper on 8/23 for the ARRO journal club. For prostate cancer it takes a long time to get a difference in OS, particularly when dealing with low or intermediate risk patients.

 

[Gfunk6]

Dr. Zietman gave a great talk on this paper on 8/23 for the ARRO journal club. For prostate cancer it takes a long time to get a difference in OS, particularly when dealing with low or intermediate risk patients.

🙂

That's nice and all but RTOG 9410 actually looked at locally advanced lung cancer (Stage IIIA/IIIB) which actually doesn't take very long at all to show differences in clinical endpoints, particularly OS.

 

[medgator]

🙂

That's nice and all but RTOG 9410 actually looked at locally advanced lung cancer (Stage IIIA/IIIB) which actually doesn't take very long at all to show differences in clinical endpoints, particularly OS.

He was probably thinking of 9413

 

[rymd]

He was probably thinking of 9413

Rather, RTOG 9408, recently published.

The word on the street is that the folks at RTOG wanted to wait until 9408 was published before they could put out 9410. Numbers are there for a reason! 😀

 

[bix]

Sorry for the confusion... I am on the prostate service so seeing prostate everywhere. I was thinking of 94-08. I need to pay attention!